Clinical Trial Update: Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan [Phase 4]

View source ↗

Summary

A Phase 4 randomized open-label trial comparing insulin degludec with insulin glargine U100 in patients with type 2 diabetes during Ramadan was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• insulin degludec (insulin degludec)
• insulin glargine U100 (insulin glargine)

Snippet

Sponsor: Weill Cornell Medical College in Qatar | Conditions: Type2 Diabetes | Phase 4 | Status: TERMINATED